SLC5A2 and type 2 diabetes mellitus: The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) adds to the studies described above by assessing the impact of SGLT2 inhibition on HF outcomes in patients shortly following an episode of decompensated HF.31 Participants enrolled in the trial had a diagnosis of T2D and were hospitalized and treated with intravenous diuretics for HF symptoms.